Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 13 March 1992:
Vol. 255. no. 5050, pp. 1437 - 1440
DOI: 10.1126/science.1371891
Prev | Table of Contents | Next

Articles

Science, Vol 255, Issue 5050, 1437-1440
Copyright © 1992 by American Association for the Advancement of Science

articles

Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex

S Nakamura, S Sakurada, SZ Salahuddin, Y Osada, NG Tanaka, N Sakamoto, M Sekiguchi, and RC Gallo

Department of Internal Medicine, University of Southern California, Los Angeles 90033.

In vitro and in vivo model systems for the study of human immunodeficiency virus (HIV)-associated Kaposi's sarcoma (KS) were used to evaluate compounds for their potential as therapeutic agents. A sulfated polysaccharide-peptidoglycan compound (SP-PG) produced by bacteria controlled the in vitro growth of acquired immunodeficiency syndrome (AIDS)-associated, KS-derived spindle-shaped cells (AIDS-KS cells) at noncytotoxic concentrations. Angiogenesis induced by AIDS-KS cells in the chicken chorioallantoic membrane assay was blocked by SP-PG, which also inhibited the vascular hyperpermeability response and the angiogenesis associated with the induction of KS-like lesions that develop after subcutaneous inoculation of AIDS-KS cells into nude mice. Suramin, pentosan polysulfate, and interferon alpha, which are currently in use for therapy of KS, were either less effective than SP-PG or much more cytotoxic, or both.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Activation of Matrix-Metalloproteinase-2 and Membrane-Type-1-Matrix-Metalloproteinase in Endothelial Cells and Induction of Vascular Permeability In Vivo by Human Immunodeficiency Virus-1 Tat Protein and Basic Fibroblast Growth Factor.
E. Toschi, G. Barillari, C. Sgadari, I. Bacigalupo, A. Cereseto, D. Carlei, C. Palladino, C. Zietz, P. Leone, M. Sturzl, et al. (2001)
Mol. Biol. Cell 12, 2934-2946
   Abstract »    Full Text »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
R. C. Gallo (1994)
JAMA 272, 916-917
   Abstract »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
S. Nakamura and S. Z. Salahuddin (1994)
JAMA 272, 917-918
   Abstract »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
S. Sakurada (1994)
JAMA 272, 918
   Abstract »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
A. Albini (1994)
JAMA 272, 919-920
   Abstract »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
P. D. Markham (1994)
JAMA 272, 920-921
   Abstract »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
J. L. Bryant (1994)
JAMA 272, 921
   Abstract »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
B. Ensoli (1994)
JAMA 272, 918-919
   Abstract »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
D. E. Koshland Jr (1994)
JAMA 272, 921-922
   Abstract »    PDF »
Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity.
M. H. Witte, P. Borgs, D. L. Way, M. Bernas, G. Ramirez Jr, and C. L. Witte (1994)
JAMA 271, 1769-1771
   Abstract »    PDF »
Kaposi's Sarcoma: Where Do We Go From Here?.
P. L. Myskowski (1993)
Arch Dermatol 129, 1320-1323
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)